% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Ernst:138141,
author = {Ernst, A. and Schlattmann, P. and Waldfahrer, F. and
Westhofen, M.},
title = {{B}21 {C}haracterisation {O}f {M}ice {O}verexpressing
{M}utant {H}untingtin {L}acking {T}he {S}pine
{M}orphogenesis {R}egulator {K}alirin-7},
journal = {Journal of neurology, neurosurgery, and psychiatry},
volume = {85},
number = {Suppl 1},
issn = {0022-3050},
address = {London},
publisher = {BMJ Publishing Group},
reportid = {DZNE-2020-04463},
pages = {A16-A16},
year = {2017},
abstract = {The BEMED study (BMJ 2016; 352: DOI 10.1136) was designed
as multi-centric, double-blind, plaebo-controlled study in
patients with Menière's disease. It should compare a
low-level (2 × 24 mg/d) vs. high-level
(3 × 48 mg/d) betahstine intake vs. placebo. The
primary endpoint was the 'number of vertigo attacks lasting
longer than 20 min as documented in a patient's diary'.
The main finding of the study was that betahistine did not
significantly better reduced the number of vertigo attacks
than placebo. Therefore, the BEMED study should be
critically discussed in the present paper.},
subtyp = {Editorial},
keywords = {Adolescent / Adult / Aged / Aged, 80 and over /
Betahistine: therapeutic use / Dose-Response Relationship,
Drug / Double-Blind Method / Female / Germany / Humans /
Male / Meniere Disease: classification / Meniere Disease:
diagnosis / Meniere Disease: drug therapy / Middle Aged /
Young Adult / Betahistine (NLM Chemicals)},
cin = {AG N.N. 3},
ddc = {610},
cid = {I:(DE-2719)1240015},
pnm = {344 - Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28850992},
doi = {10.1136/jnnp-2014-309032.49},
url = {https://pub.dzne.de/record/138141},
}